JPH09241247A - Production of 2-oxazolidinone derivative - Google Patents

Production of 2-oxazolidinone derivative

Info

Publication number
JPH09241247A
JPH09241247A JP8057396A JP8057396A JPH09241247A JP H09241247 A JPH09241247 A JP H09241247A JP 8057396 A JP8057396 A JP 8057396A JP 8057396 A JP8057396 A JP 8057396A JP H09241247 A JPH09241247 A JP H09241247A
Authority
JP
Japan
Prior art keywords
trans
phenylcyclohexyl
general formula
formula
organic solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP8057396A
Other languages
Japanese (ja)
Inventor
Hideyuki Sugimura
秀幸 杉村
Nobuko Yamada
展子 山田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Noguchi Institute
Original Assignee
Noguchi Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noguchi Institute filed Critical Noguchi Institute
Priority to JP8057396A priority Critical patent/JPH09241247A/en
Publication of JPH09241247A publication Critical patent/JPH09241247A/en
Pending legal-status Critical Current

Links

Abstract

PROBLEM TO BE SOLVED: To produce a 2-oxazolidinone derivative, easily convertible to hydroxyamino acid, which is important as a production intermediate of a medicine, by reacting with iodine as an activating agent using sodium carbonate as an alkali. SOLUTION: A β.γ-unsaturated-α-hydroxy ester of formula I (R is an alkyl; R* is a trans-2-phenylcyclohexyl) is made to react with N-ptosyl isocyanate in an organic solvent, and the obtained reaction product is treated with iodine in an organic solvent in the presence of an alkali (preferably, sodium carbonate) to form a 2oxazolidinone ring of formula II. Further, the resultant compound of formula II is made to react with tributyltin hydride in an organic solvent in the presence of azobisisobutyronitrile to obtain an objective derivative of formula III, e.g. (4R,5R)-4-[(1S)-l-iodo-2-methylpropyll-N-p-tosyl-2-oxo-5- oxazolidinecarboxylic acid (-)-trans-2-phenylcyclohexyl.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【発明の属する技術分野】本発明は、医薬品の合成中間
体として有用な α−ヒドロキシ−β−アミノ酸に誘導
可能な光学活性2−オキサゾリジノン誘導体の製造方法
に関するものである。
TECHNICAL FIELD The present invention relates to a process for producing an optically active 2-oxazolidinone derivative which is useful as a synthetic intermediate for pharmaceuticals and is capable of being converted to an α-hydroxy-β-amino acid.

【0002】[0002]

【従来の技術】2−オキサゾリジノン誘導体の合成法に
関しては、すでにアリルアルコールをN−置換 イソシ
アナートを用いてアリルカルバマートに変換後、ジエチ
ルエーテルまたは四塩化炭素中、炭酸水素ナトリウムあ
るいは炭酸カリウムの存在下ヨウ素を活性化剤として分
子内環化反応を行う方法が報告されている[平間ら、T
etrahedron Lett.、25巻、4963
ページ、1982年]。しかしながら、 光学活性な2
−オキサゾリジノン誘導体の合成や、4−アルキル−5
−カルボキシル−2−オキサゾリジノン誘導体の合成に
用いられた例はない。
2. Description of the Related Art Regarding the method for synthesizing 2-oxazolidinone derivatives, allyl alcohol has already been converted into allyl carbamate using an N-substituted isocyanate, and the presence of sodium hydrogen carbonate or potassium carbonate in diethyl ether or carbon tetrachloride. A method of performing an intramolecular cyclization reaction using lower iodine as an activator has been reported [Hirama et al., T.
etrahedron Lett. , Volume 25, 4963
Page, 1982]. However, the optically active 2
-Synthesis of oxazolidinone derivatives and 4-alkyl-5
There has been no example used for the synthesis of -carboxyl-2-oxazolidinone derivatives.

【0003】[0003]

【発明が解決しようとする課題】上記の反応を用いて光
学活性な4−アルキル−5−カルボキシル−2−オキサ
ゾリジノン誘導体が簡便に合成できれば、医薬品の製造
中間体として重要なα−ヒドロキシ−β−アミノ酸骨格
を提供する方法となることが期待される。また、その
際、新たに生じるオキサゾリジノン環の不斉炭素の立体
化学の制御が必要となる。本発明は、β,γ−不飽和α
−ヒドロキシエステルを出発原料として、N−置換イソ
シアナートの付加、引き続くカルバマートの環化によっ
て2−オキサゾリジノン誘導体を立体選択的に製造する
ことを目的とするものである。
If an optically active 4-alkyl-5-carboxyl-2-oxazolidinone derivative can be easily synthesized by using the above reaction, α-hydroxy-β-, which is important as an intermediate for the production of pharmaceuticals, can be obtained. It is expected to be a method for providing an amino acid skeleton. Further, in that case, it is necessary to control the stereochemistry of the newly generated asymmetric carbon of the oxazolidinone ring. The present invention relates to β, γ-unsaturated α
-The purpose of the present invention is to stereoselectively produce a 2-oxazolidinone derivative from a hydroxy ester as a starting material, by addition of an N-substituted isocyanate and subsequent cyclization of a carbamate.

【0004】[0004]

【課題を解決するための手段】本発明者らは、β,γ−
不飽和α−ヒドロキシエステルを原料とする2−オキサ
ゾリジノン誘導体の立体選択的な製造法を開発すべく研
究を重ねた結果、下記化4の反応行程の第2工程におい
てアルカリとして炭酸ナトリウムを用いヨウ素を活性化
剤として反応させると、立体選択的に分子内環化反応が
進行し、C4位、C5位の立体化学がアンチに制御され
た2−オキサゾリジノン誘導体が得られることを見い出
した。さらに下記化5の反応行程によってヨード基を除
去し、α−ヒドロキシ−β−アミノ酸へ変換可能な2−
オキサゾリジノン誘導体とすることによって本発明を完
成するに至った。
The present inventors have found that β, γ-
As a result of repeated research to develop a stereoselective method for producing a 2-oxazolidinone derivative using an unsaturated α-hydroxy ester as a raw material, sodium carbonate was used as an alkali and iodine was used in the second step of the reaction process of the following chemical formula 4. It has been found that when reacted as an activator, a 2-oxazolidinone derivative in which the intramolecular cyclization reaction proceeds stereoselectively and the stereochemistry at the C4 and C5 positions is anti-controlled is obtained. Furthermore, the iodo group can be removed by the reaction process of the following chemical formula 5 to convert into an α-hydroxy-β-amino acid
The present invention has been completed by using an oxazolidinone derivative.

【化4】 (一般式[4]中、Rはアルキル基を、R*はトランス
−2−フェニルシクロヘキシル基を示す。)
Embedded image (In the general formula [4], R represents an alkyl group and R * represents a trans-2-phenylcyclohexyl group.)

【化5】 (一般式[5]中、Rはアルキル基を、R*はトランス
−2−フェニルシクロヘキシル基を示す。)
Embedded image (In the general formula [5], R represents an alkyl group and R * represents a trans-2-phenylcyclohexyl group.)

【0005】すなわち本発明は一般式[1]で表わされ
るβ,γ−不飽和α−ヒドロキシエステルにN−p−ト
シルイソシアナートを反応させて得られる生成物を(第
1工程)、アルカリ存在下にヨウ素を反応させて一般式
[2]で表される2−オキサゾリジノン環を形成させ
(第2工程)、一般式[2]の化合物をアゾビスイソブ
チロニトリルの存在下水素化トリブチルスズを反応させ
る(第3工程)ことを特徴とする3工程より成る一般式
[3]で表される2−オキサゾリジノン誘導体の製造方
法に関するものである。
That is, the present invention provides a product obtained by reacting β, γ-unsaturated α-hydroxy ester represented by the general formula [1] with N-p-tosyl isocyanate (first step) in the presence of alkali. Iodine is reacted below to form a 2-oxazolidinone ring represented by the general formula [2] (second step), and the compound of the general formula [2] is converted to tributyltin hydride in the presence of azobisisobutyronitrile. The present invention relates to a method for producing a 2-oxazolidinone derivative represented by the general formula [3], which comprises three steps of reacting (third step).

【0006】以下、本発明について詳述する。The present invention will be described in detail below.

【0007】本発明方法における原料化合物であるβ,
γ−不飽和α−ヒドロキシエステルは一般式[1]で表
わされるものであり、容易に入手可能である(例えば、
特開平6−107599)。Rの具体例としては、イソ
プロピル基、シクロヘキシル基、ヘプチル基などアルキ
ル基であればよく、特に制限はない。R*の具体例とし
ては、(−)および(+)−トランス−2−フェニルシ
クロヘキシル基等の光学活性なアルコール類より導かれ
る基を挙げることができる。
Β, which is a raw material compound in the method of the present invention,
The γ-unsaturated α-hydroxy ester is represented by the general formula [1] and is easily available (for example,
JP-A-6-107599). Specific examples of R are not particularly limited as long as they are alkyl groups such as isopropyl group, cyclohexyl group and heptyl group. Specific examples of R * include groups derived from optically active alcohols such as (−) and (+)-trans-2-phenylcyclohexyl groups.

【0008】第1工程で用いるN−p−トシルイソシア
ナートの使用量は、一般式[1]で表わされる化合物1
モルに対して1.0〜1.2モルであり、非プロトン性
有機溶媒中で行い、反応温度は室温(25℃)である。
The amount of Np-tosyl isocyanate used in the first step is the amount of compound 1 represented by the general formula [1].
The amount is 1.0 to 1.2 mol, and the reaction temperature is room temperature (25 ° C.) in an aprotic organic solvent.

【0009】第2工程である分子内環化反応における塩
基としては、炭酸塩、三級アミン等を挙げることができ
るが、炭酸ナトリウムが好ましく、その使用量は、一般
式[1]で表わされる化合物1モルに対して2〜10モ
ル、好ましくは5モルである。
As the base in the intramolecular cyclization reaction which is the second step, carbonates, tertiary amines and the like can be mentioned, but sodium carbonate is preferred, and the amount thereof used is represented by the general formula [1]. The amount is 2 to 10 mol, preferably 5 mol, relative to 1 mol of the compound.

【0010】分子内環化反応におけるヨウ素の使用量
は、一般式[1]で表わされる化合物1モルに対して1
〜5モル、好ましくは2モルである。
The amount of iodine used in the intramolecular cyclization reaction is 1 with respect to 1 mol of the compound represented by the general formula [1].
-5 mol, preferably 2 mol.

【0011】環化反応は、非プロトン性有機溶媒中で行
うことができ、好ましくはアセトニトリル中で行い、反
応温度は0℃〜50℃好ましくは室温(25℃)であ
る。
The cyclization reaction can be carried out in an aprotic organic solvent, preferably in acetonitrile, and the reaction temperature is 0 ° C to 50 ° C, preferably room temperature (25 ° C).

【0012】第3工程で用いる水素化トリブチルスズは
一般式[2]で表わされる化合物1モルに対して1〜3
モル、好ましくは1.2モル、アゾビスイソブチロニト
リルは触媒量用いられ、反応温度は80℃〜120℃、
好ましくは110℃である。
Tributyltin hydride used in the third step is 1 to 3 with respect to 1 mol of the compound represented by the general formula [2].
Mol, preferably 1.2 mol, azobisisobutyronitrile is used in a catalytic amount, the reaction temperature is 80 ° C to 120 ° C,
It is preferably 110 ° C.

【0013】[0013]

【実施例】以下に、実施例を挙げて本発明を説明する。
NMRスペクトルは日本電子社製EX−400を用いて
測定した。
The present invention will be described below with reference to examples.
The NMR spectrum was measured using EX-400 manufactured by JEOL Ltd.

【0014】[0014]

【実施例1】 (4R,5R)−4−((1S)−1−ヨード−2−メ
チルプロピル)−N−p−トシル−2−オキソ−5−オ
キサゾリジンカルボン酸(−)−トランス−2−フェニル
シクロヘキシルの製造
Example 1 (4R, 5R) -4-((1S) -1-iodo-2-methylpropyl) -Np-tosyl-2-oxo-5-oxazolidinecarboxylic acid (−)-trans-2 -Production of phenylcyclohexyl

【0015】(2R)−2−ヒドロキシ−5−メチル−
3−ヘキセン酸(−)−トランス−2−フェニルシクロ
ヘキシル(1.98g,6.56mmol)のジクロロ
メタン溶液(22ml)に、アルゴン雰囲気下室温にて
N−p−トシルイソシアナート(1.90ml,7.2
2mmol)を滴下し1時間攪拌する。この混合物を減
圧下溶媒を除去し、アセトニトリル(170ml)に溶
解させ、炭酸ナトリウム(3.48g,32.8mmo
l)とヨウ素3.33g,13.1mmol)を加え、
室温で24時間撹拌する。チオ硫酸ナトリウム水溶液を
加え、炭酸水素ナトリウム水溶液で中和し、ジクロロメ
タンで抽出し、抽出液を無水硫酸マグネシウムで乾燥
後、濾過、濃縮しシリカゲルカラムクロマトグラフィー
(展開溶媒;酢酸エチル:ヘキサン=1:8)にて精製
し、(4R,5R)−4−((1S)−1−ヨード−2
−メチルプロピル)−N−p−トシル−2−オキソ−5
−オキサゾリジンカルボン酸(−)−トランス−2−フェ
ニルシクロヘキシル(3.02g,4.82mmol,
収率74%)を得る。NMRによりその構造を確認し
た。得られたスペクトルデータを下に示す。
(2R) -2-hydroxy-5-methyl-
N-p-tosyl isocyanate (1.90 ml, 7) was added to a dichloromethane solution (22 ml) of 3-hexenoic acid (-)-trans-2-phenylcyclohexyl (1.98 g, 6.56 mmol) at room temperature under an argon atmosphere. .2
(2 mmol) and the mixture is stirred for 1 hour. The solvent was removed from this mixture under reduced pressure, the residue was dissolved in acetonitrile (170 ml), and sodium carbonate (3.48 g, 32.8 mmo) was added.
l) and iodine 3.33 g, 13.1 mmol) were added,
Stir at room temperature for 24 hours. An aqueous solution of sodium thiosulfate was added, neutralized with an aqueous solution of sodium hydrogen carbonate, extracted with dichloromethane, the extract was dried over anhydrous magnesium sulfate, filtered, and concentrated. Silica gel column chromatography (developing solvent; ethyl acetate: hexane = 1: 1). 8) and purified to (4R, 5R) -4-((1S) -1-iodo-2.
-Methylpropyl) -N-p-tosyl-2-oxo-5
-Oxazolidinecarboxylic acid (-)-trans-2-phenylcyclohexyl (3.02 g, 4.82 mmol,
Yield 74%). The structure was confirmed by NMR. The spectrum data obtained is shown below.

【0016】1HNMR (CDCl3) : δ= 0.82 (d, J = 6.8 H
z, 3H), 0.93 (d, J = 6.8 Hz, 3H), 1.23-1.61 (m, 5
H), 1.79-2.08 (m, 4H), 2.46 (s, 3H), 2.68 (dt, J =
4.0,16.3 Hz, 1H), 3.83 (dd, J = 2.6, 2.8 Hz, 1H),
4.40 (dd, J = 2.8, 5.9 Hz, 1H), 4.49 (d, J = 2.6
Hz, 1H), 5.11 (dt, J = 4.0, 15.6 Hz, 1H), 7.18-7.3
4 (m, 5H), 7.36 (d, J = 8.3 Hz, 2H), 7.83 (d, J =
8.3 Hz, 2H)
1 HNMR (CDCl 3 ): δ = 0.82 (d, J = 6.8 H
z, 3H), 0.93 (d, J = 6.8 Hz, 3H), 1.23-1.61 (m, 5
H), 1.79-2.08 (m, 4H), 2.46 (s, 3H), 2.68 (dt, J =
4.0, 16.3 Hz, 1H), 3.83 (dd, J = 2.6, 2.8 Hz, 1H),
4.40 (dd, J = 2.8, 5.9 Hz, 1H), 4.49 (d, J = 2.6
Hz, 1H), 5.11 (dt, J = 4.0, 15.6 Hz, 1H), 7.18-7.3
4 (m, 5H), 7.36 (d, J = 8.3 Hz, 2H), 7.83 (d, J =
(8.3 Hz, 2H)

【0017】[0017]

【実施例2】 (4R,5R)−4−((1S)−1−ヨード−シクロ
ヘキシル)−N−p−トシル−2−オキソ−5−オキサ
ゾリジンカルボン酸 (−)−トランス−2−フェニルシ
クロヘキシルの製造
Example 2 (4R, 5R) -4-((1S) -1-iodo-cyclohexyl) -Np-tosyl-2-oxo-5-oxazolidinecarboxylic acid (-)-trans-2-phenylcyclohexyl Manufacturing of

【0018】実施例1と同様にして(2R)−2−ヒド
ロキシ−4−シクロヘキシル−3−ブテン酸(−)−ト
ランス−2−フェニルシクロヘキシル(440mg,
1.29mmol)から N−p−トシルイソシアナー
ト(0.215ml,1.40mmol)と炭酸ナトリ
ウム(684mg,6.45mmol)、ヨウ素(65
5mg,2.58mmol)を用いて標記化合物を得る
(収率67%)。NMRによりその構造を確認した。得
られたスペクトルデータを下に示す。
In the same manner as in Example 1, (2R) -2-hydroxy-4-cyclohexyl-3-butenoic acid (-)-trans-2-phenylcyclohexyl (440 mg,
1.29 mmol) to N-p-tosyl isocyanate (0.215 ml, 1.40 mmol), sodium carbonate (684 mg, 6.45 mmol), iodine (65
5 mg, 2.58 mmol) is used to obtain the title compound (yield 67%). The structure was confirmed by NMR. The spectrum data obtained is shown below.

【0019】1HNMR (CDCl3) : δ= 0.99-2.05 (m, 19
H), 2.46 (s, 3H), 2.66 (dt, J = 4.4, 11.7 Hz, 1H),
3.96 (dd, J = 2.4, 2.4 Hz, 1H), 4.43 (dd, J = 2.
4, 6.8Hz, 1H), 4.48 (d, J = 2.4 Hz, 1H), 5.15 (dt,
J = 4.4, 10.7 Hz, 1H), 7.19(d, J = 7.3 Hz, 2H),
7.241-7.36 (m, 5H), 7.83 (d, J = 8.3 Hz, 2H)
1 HNMR (CDCl 3 ): δ = 0.99-2.05 (m, 19
H), 2.46 (s, 3H), 2.66 (dt, J = 4.4, 11.7 Hz, 1H),
3.96 (dd, J = 2.4, 2.4 Hz, 1H), 4.43 (dd, J = 2.
4, 6.8Hz, 1H), 4.48 (d, J = 2.4 Hz, 1H), 5.15 (dt,
J = 4.4, 10.7 Hz, 1H), 7.19 (d, J = 7.3 Hz, 2H),
7.241-7.36 (m, 5H), 7.83 (d, J = 8.3 Hz, 2H)

【0020】[0020]

【実施例3】 (4S,5S)−4−((1R)−1−ヨードへプチ
ル)−N−p−トシル−2−オキソ−5−オキサゾリジ
ンカルボン酸 (+)−トランス−2−フェニルシクロヘ
キシルの製造
Example 3 (4S, 5S) -4-((1R) -1-iodoheptyl) -Np-tosyl-2-oxo-5-oxazolidinecarboxylic acid (+)-trans-2-phenylcyclohexyl Manufacturing of

【0021】実施例1と同様にして(2S)−2−ヒド
ロキシ−3−デセン酸(+)−トランス−2−フェニル
シクロヘキシル(1.54mg,4.48mmol)か
らN−p−トシルイソシアナート(0.75ml,4.
93mmol)と炭酸ナトリウム(2.37g,22.
4mmol)、ヨウ素(2.27g,8.96mmo
l)を用いて標記化合物を得る(収率62%)。NMR
によりその構造を確認した。得られたスペクトルデータ
を下に示す。
In the same manner as in Example 1, (2S) -2-hydroxy-3-decenoic acid (+)-trans-2-phenylcyclohexyl (1.54 mg, 4.48 mmol) to Np-tosyl isocyanate ( 0.75 ml, 4.
93 mmol) and sodium carbonate (2.37 g, 22.
4 mmol), iodine (2.27 g, 8.96 mmo)
1) is used to obtain the title compound (yield 62%). NMR
The structure was confirmed by. The spectrum data obtained is shown below.

【0022】1HNMR (CDCl3) : δ= 0.95 (t, J = 6.8 H
z, 3H), 1.09-1.60 (m, 14H), 1.78-1.82 (m, 1H), 1.8
8-1.99 (m, 2H), 2.04-2.21 (m, 1H), 2.45 (s, 3H),
2.67(dt, J = 3.9, 11.6 Hz, 1H), 3.38 (dd, J = 2.9,
2.9 Hz, 1H), 4.39 (d, J =2.9 Hz, 1H), 4.40-4.42
(m, 1H), 5.15 (dt, J = 3.9, 10.7 Hz, 1H), 7.18 (d,
J = 6.8 Hz, 2H), 7.22-7.37 (m, 5H), 7.83 (d, J =
8.3 Hz, 2H)
1 HNMR (CDCl 3 ): δ = 0.95 (t, J = 6.8 H
z, 3H), 1.09-1.60 (m, 14H), 1.78-1.82 (m, 1H), 1.8
8-1.99 (m, 2H), 2.04-2.21 (m, 1H), 2.45 (s, 3H),
2.67 (dt, J = 3.9, 11.6 Hz, 1H), 3.38 (dd, J = 2.9,
2.9 Hz, 1H), 4.39 (d, J = 2.9 Hz, 1H), 4.40-4.42
(m, 1H), 5.15 (dt, J = 3.9, 10.7 Hz, 1H), 7.18 (d,
J = 6.8 Hz, 2H), 7.22-7.37 (m, 5H), 7.83 (d, J =
(8.3 Hz, 2H)

【0023】[0023]

【実施例 4】 (4S,5R)−4−(2−メチルプロピル)−N−p
−トシル−2−オキソ−5−オキサゾリジンカルボン酸
(−)−トランス−2−フェニルシクロヘキシルの製造
Example 4 (4S, 5R) -4- (2-methylpropyl) -Np
-Tosyl-2-oxo-5-oxazolidinecarboxylic acid (-)-trans-2-phenylcyclohexyl

【0024】(4R,5R)−4−((1S)−1−ヨ
ード−2−メチルプロピル)−N−p−トシル−2−オ
キソ−5−オキサゾリジンカルボン酸(−)−トランス
−2−フェニルシクロヘキシル(610mg,0.98
mmol)をベンゼン(15ml)に溶解させ、アゾビ
スイソブチロニトリル(41.1mg,0.25mmo
l)および水素化トリブチルスズ(0.33ml,1.
18mmol)を加え、1時間還流する。冷却後濃縮
し、シリカゲルカラムクロマトグラフィー (展開溶媒;
酢酸エチル:ヘキサン=1:9)にて精製し、(4R,
5R)−4−((1S)−1−ヨード−2−メチルプロ
ピル)−N−p−トシル−2−オキソ−5−オキサゾリ
ジンカルボン酸(−)−トランス−2−フェニルシクロ
ヘキシル(478mg,0.956mmol,収率98
%)を得る。NMRによりその構造を確認した。得られ
たスペクトルデータを下に示す。
(4R, 5R) -4-((1S) -1-iodo-2-methylpropyl) -N-p-tosyl-2-oxo-5-oxazolidinecarboxylic acid (-)-trans-2-phenyl Cyclohexyl (610mg, 0.98
mmol) in benzene (15 ml) and azobisisobutyronitrile (41.1 mg, 0.25 mmo)
1) and tributyltin hydride (0.33 ml, 1.
18 mmol) and reflux for 1 hour. After cooling, the mixture is concentrated and subjected to silica gel column chromatography (developing solvent;
Purified with ethyl acetate: hexane = 1: 9, (4R,
5R) -4-((1S) -1-iodo-2-methylpropyl) -Np-tosyl-2-oxo-5-oxazolidinecarboxylic acid (-)-trans-2-phenylcyclohexyl (478 mg, 0. 956 mmol, yield 98
%). The structure was confirmed by NMR. The spectrum data obtained is shown below.

【0025】1HNMR (CDCl3) : δ= 0.82 (d, J = 6.8 H
z, 3H), 0.91 (d, J = 6.8 Hz, 3H), 1.29-1.69 (m, 7
H), 1.74-2.05 (m, 4H), 2.46 (s, 3H), 2.66 (dt, J =
3.8,16.3 Hz, 1H), 3.82 (ddd, J = 2.0, 3.4, 10.3 H
z, 1H), 4.29 (d, J = 2.0 Hz, 1H), 5.08 (dt, J = 3.
8, 10.7 Hz, 1H), 7.27-7.36 (m, 5H), 7.33 (d, J =8.
3 Hz, 2H), 7.77 (d, J = 8.3 Hz, 2H)
1 HNMR (CDCl 3 ): δ = 0.82 (d, J = 6.8 H
z, 3H), 0.91 (d, J = 6.8 Hz, 3H), 1.29-1.69 (m, 7
H), 1.74-2.05 (m, 4H), 2.46 (s, 3H), 2.66 (dt, J =
3.8, 16.3 Hz, 1H), 3.82 (ddd, J = 2.0, 3.4, 10.3 H
z, 1H), 4.29 (d, J = 2.0 Hz, 1H), 5.08 (dt, J = 3.
8, 10.7 Hz, 1H), 7.27-7.36 (m, 5H), 7.33 (d, J = 8.
3 Hz, 2H), 7.77 (d, J = 8.3 Hz, 2H)

【0026】[0026]

【実施例5】 (4S,5R)−4−シクロヘキシル−N−p−トシル
−2−オキソ−5−オキサゾリジンカルボン酸(−)−
トランス−2−フェニルシクロヘキシルの製造
Example 5 (4S, 5R) -4-Cyclohexyl-Np-tosyl-2-oxo-5-oxazolidinecarboxylic acid (-)-
Production of trans-2-phenylcyclohexyl

【0027】実施例4 と同様にして(4R,5R)−
4−((1S)−1−ヨード−シクロヘキシル)−N−
p−トシル−2−オキソ−5−オキサゾリジンカルボン
酸 (−)−トランス−2−フェニルシクロヘキシル(2
16mg,0.324mmol)からアゾビスイソブチル
ロニトリル(13,3mg,0.081mmol)と水
素化トリブチルスズ(0.11ml,0.389mmo
l)を用いて標記化合物を得る(収率93%)。NMR
によりその構造を確認した。得られたスペクトルデータ
を下に示す。
In the same manner as in Example 4, (4R, 5R)-
4-((1S) -1-iodo-cyclohexyl) -N-
p-tosyl-2-oxo-5-oxazolidinecarboxylic acid (-)-trans-2-phenylcyclohexyl (2
16 mg, 0.324 mmol) to azobisisobutyronitrile (13,3 mg, 0.081 mmol) and tributyltin hydride (0.11 ml, 0.389 mmo)
1) is used to obtain the title compound (yield 93%). NMR
The structure was confirmed by. The spectrum data obtained is shown below.

【0028】1HNMR (CDCl3) : δ= 0.78-0.99 (m, 5H),
1.11-1.89 (m, 14H), 1.95-2.12 (m, 2H), 2.46 (s,
3H), 2.65 (dt, J = 4.4, 10.0 Hz, 1H), 3.81 (ddd, J
= 1.5, 2.9, 10.3 Hz, 1H), 4.29 (d, J = 1.5 Hz, 1
H), 5.10 (dt, J = 4.4, 10.7Hz, 1H), 7.17 (d, J =
6.8 Hz, 2H), 7.21-7.37 (m, 5H), 7.77 (d, J = 8.3H
z, 2H)
1 HNMR (CDCl 3 ): δ = 0.78-0.99 (m, 5H),
1.11-1.89 (m, 14H), 1.95-2.12 (m, 2H), 2.46 (s,
3H), 2.65 (dt, J = 4.4, 10.0 Hz, 1H), 3.81 (ddd, J
= 1.5, 2.9, 10.3 Hz, 1H), 4.29 (d, J = 1.5 Hz, 1
H), 5.10 (dt, J = 4.4, 10.7Hz, 1H), 7.17 (d, J =
6.8 Hz, 2H), 7.21-7.37 (m, 5H), 7.77 (d, J = 8.3H
z, 2H)

【0029】[0029]

【実施例6】 (4R,5S)−4−ヘプチル−N−p−トシル−2−
オキソ−5オキサゾリジンカルボン酸(+)−トランス
−2−フェニルシクロヘキシルの製造
Example 6 (4R, 5S) -4-heptyl-Np-tosyl-2-
Preparation of (+)-trans-2-phenylcyclohexyl oxo-5 oxazolidine carboxylic acid

【0030】実施例4と同様にして(4R,5S)−4
−((1R)−1−ヨードヘプチル)−N−p−トシル
−2−オキソ−5オキサゾリジンカルボン酸(+)−ト
ランス−2−フェニルシクロヘキシル(1.86g,
2.78mmol)からアゾビスイソブチルロニトリル
(114mg,0.695mmol)と水素化トリブチ
ルスズ(0.93ml,3.34mmol)を用いて標
記化合物を得る(収率90%)。NMRによりその構造
を確認した。得られたスペクトルデータを下に示す。
In the same manner as in Example 4, (4R, 5S) -4
-((1R) -1-iodoheptyl) -Np-tosyl-2-oxo-5oxazolidinecarboxylic acid (+)-trans-2-phenylcyclohexyl (1.86 g,
The title compound is obtained from 2.78 mmol) using azobisisobutyronitrile (114 mg, 0.695 mmol) and tributyltin hydride (0.93 ml, 3.34 mmol) (yield 90%). The structure was confirmed by NMR. The spectrum data obtained is shown below.

【0031】1HNMR (CDCl3) : δ= 0.91 (t, J = 7.1 H
z, 3H), 1.07-1.61 (m, 14H), 1.64-1.71 (m, 2H), 1.7
9-1.89 (m, 2H), 1.95-1.98 (m, 1H), 2.04-2.07 (m, 1
H),2.45 (s, 3H), 2.65 (dt, J = 4.4, 12.1 Hz, 1H),
3.46-3.49 (m, 1H), 4.24 (d, J = 2.44 Hz, 1H), 5.0
1 (dt, J = 4.4, 10.7 Hz, 1H), 7.18 (d, J = 6.8Hz,
2H), 7.202-7.38 (m, 5H), 7.75 (d, J = 8.3 Hz, 2H)
1 HNMR (CDCl 3 ): δ = 0.91 (t, J = 7.1 H
z, 3H), 1.07-1.61 (m, 14H), 1.64-1.71 (m, 2H), 1.7
9-1.89 (m, 2H), 1.95-1.98 (m, 1H), 2.04-2.07 (m, 1
H), 2.45 (s, 3H), 2.65 (dt, J = 4.4, 12.1 Hz, 1H),
3.46-3.49 (m, 1H), 4.24 (d, J = 2.44 Hz, 1H), 5.0
1 (dt, J = 4.4, 10.7 Hz, 1H), 7.18 (d, J = 6.8Hz,
2H), 7.202-7.38 (m, 5H), 7.75 (d, J = 8.3 Hz, 2H)

【0032】[0032]

【発明の効果】本発明によって、β,γ−不飽和 α−
ヒドロキシエステルから立体選択的に2−オキサゾリジ
ノン誘導体を製造する方法を提供することが可能になっ
た。これらの2−オキサゾリジノン誘導体は、適当な脱
保護操作により、医薬品の製造中間体として重要なヒド
ロキシアミノ酸へ変換することが可能である。
According to the present invention, β, γ-unsaturated α-
It has become possible to provide a method for stereoselectively producing a 2-oxazolidinone derivative from a hydroxy ester. These 2-oxazolidinone derivatives can be converted into hydroxyamino acids, which are important as intermediates for producing pharmaceuticals, by a suitable deprotection operation.

Claims (3)

【特許請求の範囲】[Claims] 【請求項1】一般式[1] 【化1】 (一般式[1]中、Rはアルキル基を、R*はトランス
−2−フェニルシクロヘキシル基を示す。)で表される
β,γ−不飽和 α−ヒドロキシエステルに有機溶媒中、
N−p−トシルイソシアナートを反応させて得られる生
成物を有機溶媒中、アルカリ存在下にヨウ素を反応させ
て一般式[2] 【化2】 (一般式[2]中、Rはアルキル基を、R*はトランス
−2−フェニルシクロヘキシル基を示す。)で表される
2−オキサゾリジノン環を形成させ、一般式[2]の化
合物を有機溶媒中、アゾビスイソブチロニトリルの存在
下水素化トリブチルスズを反応させることを特徴とする
一般式[3] 【化3】 (一般式[3]中、Rはアルキル基を、R*はトランス
−2−フェニルシクロヘキシル基を示す。)で表される
2−オキサゾリジノン誘導体の製造方法。
1. A compound of the general formula [1] (In the general formula [1], R represents an alkyl group and R * represents a trans-2-phenylcyclohexyl group.) The β, γ-unsaturated α-hydroxy ester represented by the formula:
The product obtained by reacting Np-tosyl isocyanate is reacted with iodine in the presence of an alkali in an organic solvent to give a compound of the general formula [2] (In the general formula [2], R represents an alkyl group and R * represents a trans-2-phenylcyclohexyl group.) To form a 2-oxazolidinone ring, and the compound of the general formula [2] is converted into an organic solvent. Of the general formula [3], wherein tributyltin hydride is reacted in the presence of azobisisobutyronitrile. (In the general formula [3], R represents an alkyl group and R * represents a trans-2-phenylcyclohexyl group.) A method for producing a 2-oxazolidinone derivative.
【請求項2】アルカリとして炭酸ナトリウムを用いるこ
とを特徴とする特許請求の範囲第1項記載の製造方法。
2. The method according to claim 1, wherein sodium carbonate is used as the alkali.
【請求項3】特許請求の範囲第1項または第2項記載の
製造方法によって得られる2−オキサゾリジノン誘導
体。
3. A 2-oxazolidinone derivative obtained by the method according to claim 1 or 2.
JP8057396A 1996-03-08 1996-03-08 Production of 2-oxazolidinone derivative Pending JPH09241247A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP8057396A JPH09241247A (en) 1996-03-08 1996-03-08 Production of 2-oxazolidinone derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8057396A JPH09241247A (en) 1996-03-08 1996-03-08 Production of 2-oxazolidinone derivative

Publications (1)

Publication Number Publication Date
JPH09241247A true JPH09241247A (en) 1997-09-16

Family

ID=13722089

Family Applications (1)

Application Number Title Priority Date Filing Date
JP8057396A Pending JPH09241247A (en) 1996-03-08 1996-03-08 Production of 2-oxazolidinone derivative

Country Status (1)

Country Link
JP (1) JPH09241247A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104327007A (en) * 2014-10-20 2015-02-04 安徽师范大学 3,4,5-tri-substituted oxazolidinone compound and preparation method thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104327007A (en) * 2014-10-20 2015-02-04 安徽师范大学 3,4,5-tri-substituted oxazolidinone compound and preparation method thereof

Similar Documents

Publication Publication Date Title
KR100284216B1 (en) Asymmetric Preparation of Florfenicol, Thiamphenicol, Chloramphenicol and Oxazoline Intermediates
EP1200384B1 (en) 2-alkyl-5-halogen-pent-4-ene carboxylic acids and their production
JP4147516B2 (en) Novel intermediate compound and method for producing optically active octanoic acid derivative
EP0432504B1 (en) Process for preparing 1-(aminomethyl)cyclohexane acetic acid
JP3351563B2 (en) Method for producing 3-hydroxybutyric acid derivative
KR100205767B1 (en) Stereoselective preparation method of azetidinone
JPH09241247A (en) Production of 2-oxazolidinone derivative
Schwarz et al. Synthesis of Vicinal Stereogenic Tertiary and Quaternary Centers Using Chiral Bicyclic Lactams and Diastereoselective Protonation. Asymmetric Synthesis of (+)-Laurene
JP3097143B2 (en) Method for producing optically active compound for synthesis of physiologically active substance and optically active intermediate compound
JP2005298334A (en) Novel intermediate compound and method for manufacturing compound by using the same
KR19990008411A (en) Improvement method of 4-hydroxy-2-pyrrolidone
JP3121656B2 (en) Optically active glycidol derivative and method for producing the same
JP3081854B2 (en) Method for producing optically active levobunolol synthetic intermediate
JP3699769B2 (en) Peptide type compound
KR100420263B1 (en) Process for preparing iso-serine and its derivatives from aziridine-2-carboxylates
KR930004511B1 (en) The seperation method of alpha-halo alkanoic acid optical isomers composition
JP4266408B2 (en) Method for producing optically active glycol
JP2973546B2 (en) Optically active 4-benzoyloxymethyl-2-oxazolidinone and method for producing the same
JP3050104B2 (en) Novel method for producing 1-butyne-3,4-diol
JP2838529B2 (en) New optically active compounds
JP3060915B2 (en) trans-3-hydroxy-4-phenylthiotetrahydrofuran and process for producing the same
JP2965580B2 (en) Homostatin derivative
JP3836777B2 (en) Production method of fluorine-containing compounds
KR100524145B1 (en) Preparation methods of high purity chiral 3-hydroxy-γ-butyrolactone
DE10010984A1 (en) Preparation of 2-phenyl-4,5-dihydro-oxazole-5-carboxylic acid derivatives, used as intermediates, by catalytic cyclization of N-benzoyl-aminoalkene compound